Relay Therapeutics Jumps 16% on New Clinical Data for Its Lead Drug Outside Cancer
NEW YORK, April 8 —
Relay Therapeutics (RLAY) surged 16% to $13.48 as investors priced in a new clinical angle for its lead drug before a single slide hit the screen.
- RLAY shares jumped 16% ahead of initial clinical data on Zovegalisib in vascular anomalies at the ISSVA World Congress 2026
- The company trades at $13.48 with just $15mn in TTM revenue and a negative forward P/E of -8.7x
- The ISSVA presentation will be the first clinical readout for Zovegalisib outside of oncology
What Actually Happened
Relay announced it will present initial clinical data on Zovegalisib, a PI3Kα inhibitor, in patients with vascular anomalies at the ISSVA World Congress. This is the drug's first readout outside cancer indications, where it has been the company's lead pipeline asset. The market treated this as a platform validation event. If a single molecule works across two unrelated disease areas, the probability-weighted value of the entire pipeline goes up.
Vascular anomalies are a collection of rare disorders involving abnormal blood vessel growth. PI3Kα is a known driver of several subtypes, so the biological rationale is real. Novartis already sells Alpelisib (a PI3Kα inhibitor) for PIK3CA-related overgrowth spectrum under the brand Vijoice, proving the pathway works. Relay is chasing a validated target, not a novel one.
The Catch
A 16% move on a pre-data announcement is the market writing a check the trial hasn't cashed yet. We have zero efficacy numbers, zero safety data. This is a stock trading on the promise of a conference poster. Relay generates $15mn in TTM revenue against what is almost certainly a heavy cash burn profile typical of clinical-stage biotech. The negative forward P/E confirms the company is not expected to turn profitable anytime soon. If the ISSVA data disappoints, or shows a safety signal that limits dosing, this 16% gives back fast. Novartis has the head start, the sales force, and the regulatory precedent in this exact pathway.
Bottom Line
This is a legitimately interesting development for Relay's platform story. Showing Zovegalisib works outside oncology would transform the company from a one-trick pipeline play into a multi-indication platform, and that distinction matters for partnership and acquisition discussions. But at $13.48 on $15mn in revenue, you are buying a story, not a business. The number to watch is the actual response rate in vascular anomalies patients at ISSVA. Everything else is noise until then.
Relay Therapeutics doesn't have a Basis Report yet. Generate a full RLAY analysis here to see how the pipeline stacks up.
Basis Report does not hold positions in securities discussed. This is not investment advice.